Valeant Response `Deeply Disappointing,' Senator McCaskill Says

Valeant Pharmaceuticals International Inc. failed to provide satisfactory answers to an inquiry about its price increases for medications it acquired, Senator Claire McCaskill said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.